Who is sponsoring NCT04815720?

NCT04815720 is sponsored by Vaccinex Inc..

What drugs are being tested in NCT04815720?

Interventions in NCT04815720: pepinemab + pembrolizumab.

Is NCT04815720 still recruiting?

NCT04815720 is currently completed. Last updated 8 January 2025.

Last reviewed 2025-01-08 · How we verify

NCT04815720: KEYNOTE-B84

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed Phase 1, PHASE2 Last updated 8 January 2025

What this trial tests

Phase 1, PHASE2 trial testing pepinemab + pembrolizumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) in 49 participants. Completed in 24 July 2024.

Timeline

9 August 2021

Primary endpoint
24 July 2024

24 July 2024

Quick facts

Lead sponsor	Vaccinex Inc.
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	49
Start date	9 August 2021
Primary completion	24 July 2024
Estimated completion	24 July 2024
Sites	15 locations across United States

Drugs / interventions tested

pepinemab + pembrolizumab — full drug profile →

Conditions studied

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) — all drugs for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) →

Sponsor

Vaccinex Inc. — full company profile →

Who can join

Adults 18 to 100, any sex, with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Ghosh S, Shah PA, Johnson FM. · · 2022 · cited 47× · PMID 35887235 · DOI 10.3390/ijms23147889
Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma.
Lee AM, Weaver AN, Acosta P, Harris L, et al · · 2024 · cited 17× · PMID 39456583 · DOI 10.3390/cancers16203488
Overcoming Resistance to Standard-of-Care Therapies for Head and Neck Squamous Cell Carcinomas.
Gauss C, Stone LD, Ghafouri M, Quan D, et al · · 2024 · cited 10× · PMID 38920648 · DOI 10.3390/cells13121018
Immune biomarkers for head and neck cancer.
Sobhani N, D'Angelo A, Kugeratski FG, Nguyen T, et al · · 2025 · cited 1× · PMID 41410866 · DOI 10.1007/s00262-025-04233-7

Verify or expand the search:

Other Vaccinex Inc. trials

Trials by the same sponsor.

NCT05102721 — Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma · Phase 1, PHASE2 · active not recruiting
NCT04381468 — SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) · Phase 1, PHASE2 · completed
NCT03268057 — VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04815720 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vaccinex Inc.
Last refreshed: 8 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04815720.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing